IN PARTNERSHIP WITH THE UNIVERSITY OF TORINO AND MCGILL UNIVERSITY
Expanding bRo5 chemical space and accurately modeling ternary complex stability are key
In collaboration with the University of Turin (Italy) and McGill University, we are constructing an automated, end-to-end in silico platform aimed at significantly enhancing the success rate of PROTACs and molecular glues to clinical trials.
This platform will have the capacity to design and characterize in silico the degradation activity, pharmacokinetics, and physicochemical properties of 200k candidates annually, a hundredfold increase over current available structures.